GILD - Gilead Sciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
73.32
+0.96 (+1.33%)
At close: 4:00PM EDT

72.51 -0.81 (-1.10%)
After hours: 7:34PM EDT

Stock chart is not supported by your current browser
Previous Close72.36
Open72.37
Bid72.51 x 800
Ask73.00 x 1000
Day's Range72.37 - 73.48
52 Week Range64.27 - 89.54
Volume8,209,081
Avg. Volume6,829,812
Market Cap95.048B
Beta1.45
PE Ratio (TTM)43.80
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.28 (3.13%)
Ex-Dividend Date2018-09-13
1y Target EstN/A
Trade prices are not sourced from all markets
  • Japan Nods to AstraZeneca's Tagrisso for First-Line NSCLC
    Zacks6 hours ago

    Japan Nods to AstraZeneca's Tagrisso for First-Line NSCLC

    AstraZeneca (AZN) receives approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the label expansion of Tagrisso.

  • Alexion's BLA for ALXN1210 Gets Priority Review From FDA
    Zacks13 hours ago

    Alexion's BLA for ALXN1210 Gets Priority Review From FDA

    The FDA grants priority review to Alexion's (ALXN) BLA for its C5 complement inhibitor ALXN1210 with respect to the treatment of patients with paroxysmal nocturnal hemoglobinuria.

  • The Zacks Analyst Blog Highlights: Amazon, Petroleo Brazileiro, Gilead Sciences and KLA-Tencor
    Zacks16 hours ago

    The Zacks Analyst Blog Highlights: Amazon, Petroleo Brazileiro, Gilead Sciences and KLA-Tencor

    The Zacks Analyst Blog Highlights: Amazon, Petroleo Brazileiro, Gilead Sciences and KLA-Tencor

  • The Cost of Cures: How Investing in Biotech Stocks Could Soon Be Radically Changed
    Motley Fool17 hours ago

    The Cost of Cures: How Investing in Biotech Stocks Could Soon Be Radically Changed

    Get ready for a golden age of medicine that could dramatically shake up which biotechs get the gold.

  • Novo Nordisk Buys Ziylo to Develop Glucose Responsive Insulin
    Zacksyesterday

    Novo Nordisk Buys Ziylo to Develop Glucose Responsive Insulin

    Novo Nordisk A/S (NVO) acquires Ziylo Ltd. to speed up the development of glucose responsive insulins in a deal that could exceed $800 million.

  • Examining Amgen’s Revenue Trend in Q2 2018
    Market Realistyesterday

    Examining Amgen’s Revenue Trend in Q2 2018

    As we discussed earlier, Amgen (AMGN) reported a 4% rise in its year-over-year revenue to ~$6.06 billion in the second quarter compared to $5.81 billion in the first quarter of 2017. Amgen surpassed analysts’ estimates for EPS and revenue in the second quarter, reporting non-GAAP (generally accepted accounting principles) EPS of $3.83 on revenue of ~$6.1 billion compared to the estimate of $3.54 on revenue of $5.7 billion.

  • A Look at Amgen’s Valuation on August 20
    Market Realistyesterday

    A Look at Amgen’s Valuation on August 20

    Amgen (AMGN) is a leading biotechnology company focused on discovering, developing, manufacturing, and delivering human therapeutics.

  • 8 Undervalued Biotech Stocks to Watch
    InvestorPlace2 days ago

    8 Undervalued Biotech Stocks to Watch

    From an overall perspective, biotech stocks have enjoyed respectable gains this year. The sector exchange-traded fund SPDR S&P Biotech ETF (NYSEARCA:XBI) is up double digits since January’s opening session. That said, the market movement has been anything but steady, with several key players suffering disappointing performances.

  • Is Viking Therapeutics, Inc. a Buy?
    Motley Fool3 days ago

    Is Viking Therapeutics, Inc. a Buy?

    No gnashing of teeth needed to make a call on this clinical-stage biotech.

  • Stanley Druckenmiller Bets on Facebook and Oil
    GuruFocus.com4 days ago

    Stanley Druckenmiller Bets on Facebook and Oil

    Stanley Druckenmiller (Trades, Portfolio)'s Duquesne Capital spent purchased 19 new stocks in the second quarter, with his biggest purchase being of Facebook (FB), he revealed Wednesday. Warning! GuruFocus has detected 5 Warning Signs with SPLK.

  • Biogen Expected to Report Robust Rise in Diluted EPS in 2018
    Market Realist4 days ago

    Biogen Expected to Report Robust Rise in Diluted EPS in 2018

    In its Q2 2018 earnings conference call, Biogen (BIIB) updated its 2018 GAAP EPS guidance from the previously projected range of $22.20–$23.20 to $21.80–$22.40, which implies a YoY (year-over-year) rise of 83%–87%.

  • Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?
    Zacks5 days ago

    Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?

    Is (GILD) Outperforming Other Medical Stocks This Year?

  • Considering Allergan’s Q2 2018 Revenue Trend
    Market Realist5 days ago

    Considering Allergan’s Q2 2018 Revenue Trend

    As discussed earlier, Allergan (AGN) reported a 2.9% rise in its YoY (year-over-year) revenue to $4.1 billion in the second quarter compared to $4.0 billion in the second quarter of 2017.

  • Analyst Recommendations for Biogen and Its Peers in August
    Market Realist5 days ago

    Analyst Recommendations for Biogen and Its Peers in August

    On July 25, Biogen (BIIB) and Eisai announced positive results from the Phase 2 study evaluating BAN2401, an investigational anti-amyloid-beta (or Aβ) protofibril antibody, in early Alzheimer’s disease (or AD) indication after 18 months of therapy. The patients also included those suffering from AD-related mild cognitive impairment as well as those with mild AD. The results from the Phase 2 trial seem to validate beta-amyloid as a potential target for treating Alzheimer’s disease.

  • Why Vertex Is Expected to Report Robust EPS Growth in 2018
    Market Realist6 days ago

    Why Vertex Is Expected to Report Robust EPS Growth in 2018

    How Is Vertex Pharmaceuticals Positioned in August? In its Q2 2018 earnings conference call, Vertex Pharmaceuticals (VRTX) reiterated its projection for non-GAAP combined selling, general, and administrative (or SG&A) and research and development (or R&D) expenses to come in in the range of $1.5 billion and $1.55 billion for fiscal 2018. In Q2 2018, the company reported non-GAAP combined R&D and SG&A expenses close to $388 million.

  • Vertex Pharmaceuticals Is Expected to See Robust Revenue Growth
    Market Realist6 days ago

    Vertex Pharmaceuticals Is Expected to See Robust Revenue Growth

    In its Q2 2018 earnings conference call, Vertex Pharmaceuticals (VRTX) updated its revenue guidance for fiscal 2018 from the previously projected range of $2.65 billion–$2.8 billion to $2.9 billion–$3.0 billion. The midpoint of this guidance range would imply a 36% year-over-year (or YoY) rise in revenues in fiscal 2018. This expectation has mainly been driven by the solid adoption of Symdeko since its launch in US markets. The company has not assumed the impact of securing new reimbursement for its CF drugs in markets outside the US in its fiscal 2018 revenue guidance.

  • Vertex's Cystic Fibrosis Drug Gets FDA Nod for Children
    Zacks6 days ago

    Vertex's Cystic Fibrosis Drug Gets FDA Nod for Children

    Vertex's (VRTX) cystic fibrosis drug, Kalydeco gets FDA approval to treat children aged 12 months to two years

  • Should Gilead Be Worried About This New Monthly HIV Medication?
    Motley Fool6 days ago

    Should Gilead Be Worried About This New Monthly HIV Medication?

    The devil is in the undisclosed details.

  • Long-acting injection a shot in the arm for GSK's HIV business
    Reuters6 days ago

    Long-acting injection a shot in the arm for GSK's HIV business

    A long-acting injection developed by GlaxoSmithKline and given once a month has proved as effective as standard daily pills for controlling the AIDS virus, lifting prospects for the British drugmaker's key HIV business. GSK's majority-owned ViiV Healthcare unit said on Wednesday the experimental two-drug injection of cabotegravir and rilpivirine maintained similar rates of viral suppression compared with a standard three-drug oral regimen, after 48 weeks of a clinical trial. GSK hopes its new approach will allow it to compete more effectively against Gilead Sciences, the U.S. drugmaker that dominates the $26 billion-a-year HIV market.

  • Long-acting injection a shot in the arm for GSK's HIV business
    Reuters7 days ago

    Long-acting injection a shot in the arm for GSK's HIV business

    A long-acting injection developed by GlaxoSmithKline and given once a month has proved as effective as standard daily pills for controlling the AIDS virus, lifting prospects for the British drugmaker's key HIV business. GSK's majority-owned ViiV Healthcare unit said on Wednesday the experimental two-drug injection of cabotegravir and rilpivirine maintained similar rates of viral suppression compared with a standard three-drug oral regimen, after 48 weeks of a clinical trial. GSK hopes its new approach will allow it to compete more effectively against Gilead Sciences, the U.S. drugmaker that dominates the $26 billion-a-year HIV market.

  • Reuters7 days ago

    Congo deploys experimental Ebola treatment as cases rise

    GOMA, Democratic Republic of Congo/GENEVA, Aug 14 (Reuters) - D emocratic Republic of Congo has started using the experimental mAb114 Ebola treatment to counter the latest flare-up of the virus, health officials said on Tuesday, the first time it has been deployed against an active outbreak. Forty-two people are believed to have died from the haemorrhagic fever in Congo's tenth Ebola outbreak since it was discovered in the 1970s. In all, there have been 66 cases to date, including 39 confirmed and 27 probable, the health ministry said on Tuesday evening, an increase of nine confirmed cases since Monday.

  • After five months on job, Gilead chief medical officer joins exodus
    American City Business Journals7 days ago

    After five months on job, Gilead chief medical officer joins exodus

    Dr. Andrew Cheng, appointed in March as chief medical officer of Gilead Sciences Inc., is leaving the company, joining an exodus of top-level executives from the Foster City-based drug developer. Cheng will "pursue another opportunity," Gilead (NASDAQ: GILD) said Tuesday while disclosing two promotions. Dr. Diana Brainard was promoted from vice president of clinical research, to senior vice president of HIV and emerging viral infections, and Gregg Alton, executive vice president of corporate and medical affairs, will become Gilead's first chief patient officer.

  • Shire, Shionogi File NDA for Intuniv for Adults in Japan
    Zacks8 days ago

    Shire, Shionogi File NDA for Intuniv for Adults in Japan

    Shire's (SHPG) Japanese partner Shionogi & Co., Ltd submits a new drug application for Intuniv in Japan for the treatment of attention deficit hyperactivity disorder (ADHD) in adults.

  • Amicus (FOLD) Gets FDA Nod for Fabry Disease Drug Galafold
    Zacks9 days ago

    Amicus (FOLD) Gets FDA Nod for Fabry Disease Drug Galafold

    Amicus (FOLD) gets a major boost with the FDA approval of lead candidate, Galafold (migalastat) 123 mg capsules for the treatment of Fabry disease.

  • Biotech ETFs in Focus on String of Q2 Earnings Beat
    Zacks11 days ago

    Biotech ETFs in Focus on String of Q2 Earnings Beat

    Biotech ETFs draw attention post impressive Q2 results.